DMIIU
Drugs Made In America Acquisition II Corp. UnitNASDAQNONENONE
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
—
52W High
$0.00
52W Low
$0.00
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition II Corp. Unit
Drugs Made In America Acquisition II Corp. (DMIIU) is a special purpose acquisition company (SPAC) dedicated to merging with and advancing companies within the pharmaceutical and biotechnology industries. The firm focuses on enhancing domestic drug manufacturing and fostering innovation in healthcare by strategically investing in entities with disruptive technologies and proven operational excellence. With a commitment to tackling critical industry challenges, DMIIU is well-positioned to generate substantial shareholder value while contributing to the evolution of the American healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
1.29%
HV 20-Day
1.01%
HV 30-Day
1.11%
HV 60-Day
3.45%
HV Rank
—
Volatility is currently expanding
More NONE Stocks
SOJESouthern Company (The) Series 2DTGDTE Energy Company 2021 Series EDTBDTE Energy Company 2020 SeriesCGABLThe Carlyle Group Inc. 4.625% Subordinated Notes due 2061MGRBAffiliated Managers Group, Inc.NIQNIQ Global Intelligence plcUZFUnited States Cellular CorporatUZDUnited States Cellular CorporatRILYTB. Riley Financial Inc. 6.00% Senior Notes Due 2028HWCPZHancock Whitney Corporation - 6OXLCLOxford Lane Capital Corp. 6.75% Notes due 2031BBBYBed Bath & Beyond, Inc.
Data last updated: 5/2/2026